🇺🇸 FDA

Drug profile · INN

granisetron

SANCUSO

approved A04AA02
US status
approved
Patents linked
3
News articles
0

Quick answer

granisetron (SANCUSO) is an FDA-listed pharmaceutical active ingredient. Associated with Heron Therapeutics. Route of administration: subcutaneous. Current US regulatory status: approved.

Key facts

INN granisetron
Brand SANCUSO
Route SUBCUTANEOUS
Formulation INJECTABLE
ATC code A04AA02
Originator Heron Therapeutics

Related patents

Search patents →

  1. US 10357570

    Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9913910

    Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron

    Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8715710

    Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron

    Expires Mon May 01 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is granisetron?

granisetron (SANCUSO) is an FDA-listed pharmaceutical active ingredient. Associated with Heron Therapeutics. Route of administration: subcutaneous. Current US regulatory status: approved.

What is the brand name for granisetron?

SANCUSO is a marketed brand name for granisetron. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of granisetron?

granisetron has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.